First Neurogenic Orthostatic Hypotension Drug Launched

First Neurogenic Orthostatic Hypotension Drug Launched
First Neurogenic Orthostatic Hypotension Drug Launched

Lundbeck announced the availability of Northera (droxidopa) capsules for the treatment of orthostatic dizziness and lightheadedness in adult patients with symptomatic neurogenic orthostatic hypotension (NOH) caused by primary autonomic failure (eg, Parkinson's disease, multiple system atrophy, pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. Northera is the only approved therapy for this condition.

Droxidopa, a synthetic amino acid analog, is believed to exert its pharmacological effects through norepinephrine and not through the parent molecule or other metabolites. Norepinephrine increases blood pressure by inducing peripheral arterial and venous vasoconstriction. The exact mechanism of action in the treatment of neurogenic orthostatic hypotension is unknown.

RELATED: First Neurogenic Orthostatic Hypotension Drug OK'd in Two Decades

Northera is available through specialty pharmacies across the country. It is available in 100mg, 200mg, and 300mg capsules in 90-count bottles.

For more information call (844) 601-0101 or visit Northera.com.

Loading links....